Search

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Low-WAC interchangeable biosimilar is now available

Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.

Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction

Jardiance® (empagliflozin) analysis reinforces established safety profile

A Brave New World: Digital Health Redo | Boehringer Ingelheim US

Find out more on how digital innovation in Boehringer Ingelheim is transforming the world of animal health, including disease prevention and vaccination.

New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies

FDA approves additional formulation of biosimilar

US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.

Talking drug discovery with our U.S. research site head, Carine Boustany

Learn about the challenges and victories of developing new medicine for conditions, like generalized pustular psoriasis (GPP) flares in adults.

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US

Boehringer Ingelheim and Eli Lilly and Company today announced that the EMPEROR HF (heart failure) clinical trial program was initiated.

NASH

Interchangeable Biosimilar Now on Express Scripts® Formulary

Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary

HEARTGARD Plus Save A Heart Initiative | Boehringer Ingelheim US

See how Boehringer Ingelheim, the maker of HEARTGARD Plus, is flying at risk dogs to new homes across the US to celebrate Heartworm Disease Awareness Month

U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes

Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats

Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure

Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia

New agreement with Quallent expands biosimilar access

Boehringer Ingelheim enters private label agreement for biosimilar

Deciphering Circuits in Neuroscience | Boehringer Ingelheim US

Hear from Craig Lindsley, Director of the Warren Center for Neuroscience Drug Discovery on our dedication to improving mental health.

New affordability initiative with GoodRx for our biosimilar

Boehringer Ingelheim announces patient affordability initiative with GoodRx for biosimilar

Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

FDA Approves Jardiance® (empaglifozin) for T2D | BI US

Read more about the approval of Boehringer Ingelheim's third product from the BI-Lilly Diabetes alliance, JARDIANCE, used to treat type-2 diabetes.

Livestock

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers